Search
forResearch 10 of 45
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
- Treatment of actinic cheilitis with ingenol mebutate gel: Experience in four patients
- 8 Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →